

NEBRASKA ACCOUNTABILITY AND DISCLOSURE COMMISSION 1225 L St., Suite 400 P.O. Box 95086 Lincoln, NE 68509 (402) 471-2522 www.nadc.nebraska.gov	STATEMENT OF FINANCIAL INTERESTS NADC FORM C-1	POSTMARK DATE		MICROFILM NUMBER	
BEFORE COMPLETING READ FILING REQUIREMENTS		OFFICE USE ONLY			
- Candidates for designated offices and holders of designated offices and positions must file this statement with the Commission. See Sections 1A and 1B of the instructions. - Candidates (including incumbents) subject to this filing requirement must file this statement in order to have their names appear on the ballot. (See Instructions). - Designated officeholders and holders of designated positions must file this statement with the Commission annually. - Dollar values need not be report for any item, except Item 11. - Persons who fail to file as required are subject to a civil penalty of up to \$2,000.					
ITEM 1 YOUR NAME, ADDRESS AND PHONE NUMBER					
Name <u>Blowers</u> Charles Eric Telephone No. 308-529-1972					
LAST FIRST MIDDLE					
Address 41093 Road 790 Gothenburg NE 69138					
STREET ADDRESS OR RURAL ROUTE CITY STATE ZIP CODE					
ITEM 2 OCCASION FOR FILING (Check Appropriate Box)					
A ☐ candidate for elective office Left office or ☐ position Annual ☒ officeholder's or state employee's report ☐ Newly appointed to office or position					
ITEM 3 OFFICE HELD & TERM OF OFFICE (Incumbent elected/appointed officials and state employees. See IB of instructions)					
List the office or position you currently hold which requires this filing. If you have left office, list the office you held.					
Office or Position: County Supervisor Term: 2023 2026					
BEGINS ENDS					
Name of City, County, District, or State Agency: Custer County					
ITEM 4 OFFICE SOUGHT (Candidates only. See 1A of instructions)					
List the office sought which requires this filing.					
Office: County Supervisor					
Name of City, County, District, or State Office: Custer					
ITEM 5 PERIOD COVERED BY THIS STATEMENT					

This statement must cover all financial interests for the entire "preceding calendar year" and not just as of year-end. If you have left office, this statement must cover all financial interests from the end of the calendar year for which you previously filed up to and including the date you left office.

☒ This statement covers the **preceding calendar year** January 1 through December 31, 2025

☐ Left office, this statement covers the period January 1, _____ to _____

(DATE YOU LEFT OFFICE OR POSITION)

ITEM 6 | SOURCES OF INCOME OF OVER \$1,000

Income includes money or any other form of recompense constituting income under the Internal Revenue Code. (See definitions)

Name and address of any source* (including an individual, business, body of government, political subdivision or body corporate) from which income of over \$1,000 was received.

List the nature of the source's business and the nature of the services you rendered or the circumstances under which income was received. NOTE: Do not list the amount of the income.

List your Government position if you were paid more than \$1,000.1.) Custer County Supervisor
431 South 10th Ave
Broken Bow, NE 688221a.) 4 Year Term as county supervisor for Custer County2.) _____
_____2a.) _____
_____3.) _____
_____3a.) _____
_____4.) _____
_____4a.) _____
_____***NOTE: IF INCOME RESULTED FROM EMPLOYMENT BY, OPERATION OF OR PARTICIPATION IN A PROPRIETORSHIP, PARTNERSHIP, CORPORATION OR OTHER PERSON, LIST THE SAME AS THE SOURCE OF INCOME, BUT NOT THE PATRONS, CUSTOMERS, PATIENTS, OR CLIENTS THEREOF.****ITEM 7 | BUSINESSES WITH WHICH YOU ARE ASSOCIATED Including Non Profits (See definitions)**

Name and address of all businesses, organizations, or associations (profit and non-profit) with which you held a position of officer, director, limited liability company member, partner, or stockholder and any entity in which you held a position of trustee. Such reporting is required based on the position held, not on whether income was received. You need not report business associations which are otherwise listed under Item 6.

Name and Address of Business or Organization.

Nature of Association

If you have nothing to report, write NONE1.) Blowers Farms LLC
79031 Road 412
Gothenburg, NE 691381a.) Co-Manager of Farming and Ranching Operation2.) Blowers Investments LLC
79031 Road 412
Gothenburg, NE 691382a.) Co-Owner3.) BK Development
Kearney, NE3a.) Co-Owner

4.) _____

4a.) _____

5.) _____

5a.) _____

6.) _____

6a.) _____

7.)	7a).

ITEM 8	REAL PROPERTY OF THE FILER IN NEBRASKA (Real property valued at less than \$1,000 and your personal residence need <i>not</i> be reported.)	
List all real property in Nebraska in your name or in which you have a direct ownership interest. The description required must be sufficient to identify the location of the property. Exceptions: You need not report real property owned by a business listed in Item 6 or 7, your personal residence or real property valued at less than \$1,000. Personal residence refers to your principal dwelling-house and adjacent land used for house-hold purposes, such as lawns and gardens.		
	Location of Property (Description or Address)	Nature of Property (such as: agricultural, commercial, industrial, residential-rental)
If you have nothing to report, write NONE		
	3 15 25 SEC 3-15-25 SW1/4 160 ACRES ELIM TWP, 3 15 25 SEC 3-15-25 S1/2NW, LOTS 3-4 160.27 ACRES ELIM TWP	Agriculture

ITEM 9	OTHER FINANCIAL INTERESTS AND PROPERTY HELD DURING THE PERIOD OF THIS STATEMENT WHICH EXCEEDED A FAIR MARKET VALUE OF \$1,000 AT ANY TIME DURING THE REPORTING PERIOD	
(a) List the names and addresses of the institutions in which you had checking and savings accounts and certificates of deposit.		
	Financial Institution	Address
If you have nothing to report, write NONE		
	Farm Credit Services of America North Platte, NE Nebraskaland Bank North Platte, NE Pinnacle Bank Arnold, NE	Flatwater Bank Gothenburg, NE
(b) List the names of the issuers of all stocks, bonds, and government securities, not otherwise listed under Items 6 or 7.		
If you have nothing to report, write NONE		

None

(c) Describe other property owned or held for the production of income not otherwise disclosed in Items 6, 7, 8 or 9(a)(b). Include leaseholds and other interests in real estate, promissory notes and other obligations owed to you, beneficial interests in trusts and estates, cash value life insurance, IRAs, deferred income and retirement plans. Exception: Do not include accounts receivable, inventory, fixtures and equipment owned or used by a business listed in Items 6 & 7 or household goods, personal automobiles and other tangible personal property unless such property was held primarily for sale or exchange.


If you have nothing to report, write NONE

IRA
Edward Jones
Gothenburg, NE 69138

ITEM 10	CREDITORS TO WHOM \$1,000 OR MORE WAS OWED OR GUARANTEED BY YOU OR A MEMBER OF YOUR IMMEDIATE FAMILY.		
Exception: Loans from a relative and land contracts which have been recorded with the County Clerk or Register of Deeds need not be reported. Accounts payable, debts arising out of retail installment transactions or loans made by a financial institution in the ordinary course of business need not be reported.			
Name		Address	
If you have nothing to report, write NONE			
NONE			
ITEM 11	SOURCES OF GIFTS OF A VALUE OF MORE THAN \$100 RECEIVED EXCEPT GIFTS FROM RELATIVES. (See definitions) If you have nothing to report, write NONE		
Name and address of Donor	Occupation or nature of business of Donor	Value of Gift (See Key Below)	Description of Gift and Circumstances or Occasion for Gift
If you have nothing to report, write NONE			
NONE		Choose Value:	
		Choose Value:	
		Choose Value:	
		Choose Value:	
		Choose Value:	
		Choose Value:	
		Choose Value:	
		Choose Value:	

The monetary value of each gift shall be categorized based on the good faith estimate of the filer. For each reported gift insert in the Value column the letter which corresponds to the value category of the gift. The value categories are:

A) \$100.01 to \$200; B) \$200.01 to \$500; C) \$500.01 to \$1,000; D) \$1,000.01 or more.

ITEM 12	SIGNATURE OF FILER AND DATE.
I hereby state that I have used all reasonable diligence in the preparation of this Statement and that to the best of my knowledge it is true and complete.	
	2-26-26
(Signature of Filer)	(Date)

Criminal Penalties: Any person who files a statement knowing that information is false shall be guilty of a Class IV Felony, See §49-14,134, Nebraska Revised Statutes.

General Information - Filing Requirements

I. Who Should File:

A. Candidates for the offices of Governor, Lt. Governor, Attorney General, Auditor of Public Accounts, Secretary of State, State Treasurer, State Board of Education, Public Service Commission, Board of Regents of the University of Nebraska, State Legislature, Board of Directors of a Public Power District, Mayor and City Council of the cities of Omaha and Lincoln, and any elective county office.

B. Officeholders

1. Any person holding an office listed in 1A above.
2. A member of a land use planning commission or zoning commission of any county with a population of more than 100,000 residents.
3. State officeholders, state officials and state employees specified in §49-1493 of the Nebraska Statutes or Title 4, Chapter 2 of the Commission's rules and regulations.

II. When and Where to File:

A. Candidates for the elective offices listed in 1A, above, should file with the Commission by **March 1st** of the year of the election. The filing must cover the calendar year prior to the election. **Failure to file a Statement of Financial Interests as required may result in the candidate's name not appearing on the ballot.**

B. Special Note: A candidate who files during the calendar year before the election to appear on the ballot must file two Statements with the Commission. The first must cover the calendar year prior to the date of filing to appear on the ballot. The second must be filed by March 1st of the year of the election and must cover the calendar year prior to the year of the election. **Failure to file a Statement of Financial Interests as required may result in the candidate's name not appearing on the ballot.**

C. Officeholders, officials and employees referred to in 1B, above, must file with the Commission on or before **March 1st** of each year in which they hold the position.

D. Officeholders, officials and employees referred to in 1B, above, who are appointed to the position must file with the Commission prior to assuming the duties of the office or position. If confirmation is required, the filing should be made prior to assuming the duties of office or position or prior to confirmation, whichever comes first. This filing need not be made with the election official.

E. Within 30 days after leaving an office or a position listed in 1B, above, a statement should be filed with the Commission. The filing should cover a period beginning with the closing date of the prior statement through the date that the person left the office or position. This filing need not be made with the election official.

III. Potential Conflict of Interest Filings:

The individuals listed under 1B above are required to file a Potential Conflict of Interest Statement (NADC Form C-2)) whenever a potential conflict of interest arises. A public official or public employee has a potential conflict of interest if he or she is faced with taking an official action or making an official decision which could result in a financial benefit or financial detriment to: a) the public official; b) a member of his or her immediate family; or c) a business with which he or she is associated. The financial benefit must be distinguishable from that experienced by the general public or a broad segment of it.

IV. FORMS:

A. Hard copies of forms may be obtained by contacting the Commission office. Forms may also be obtained from the Commission's website at www.nadc.nebraska.gov.

B. Forms may be downloaded onto a computer hard drive, completed, printed, and mailed or otherwise sent to the Commission. A copy of the filing may be preserved on the hard drive of a computer for future reference.

Definitions

Business - means any corporation, partnership, limited liability company, sole proprietorship, firm, enterprise, franchise, association, organization, self-employed individual, holding company, joint stock company, receivership, trust, activity or entity.

Business with which the individual is associated - means a business (1) in which the individual is a partner, Limited Liability Company Member, director, or officer, or (2) in which the individual or a member of the individual's immediate family is a stockholder of closed corporation stock worth one thousand dollars or more at fair market value or which represents more than a five percent equity interest, or is a stockholder of publicly traded stock worth ten thousand dollars or more at fair market value or which represents more than ten per cent equity interest. An individual who occupies a confidential professional relationship protected by law shall be exempt from this section. This section shall not apply to publicly traded stock under a trading account if the filer reports the name and address of the stockbroker.

Elective office - means a public office filled by an election, except for federal offices. A person who is appointed to fill a vacancy in a public office which is ordinarily elective holds an elective office.

Financial Institution - As used in section 49-1496, financial institution means a bank, savings bank, building and loan association, savings and loan association, or credit union, whether chartered by the United States, the department, or a foreign state agency; any other similar organization which is covered by federal deposit insurance; or a trust company. See section 8801.03(11) of the state statutes.

Gift - means a payment, subscription, advance, forbearance, rendering or deposit of money, services, or anything of value, unless consideration of equal or greater value is given therefor. Gift shall not include a campaign contribution otherwise reported as required by law, a commercially reasonable loan

1. The purpose of this report is to provide a comprehensive overview of the current state of the global economy, focusing on the impact of the COVID-19 pandemic. The report will analyze the economic challenges faced by various countries and regions, as well as the potential for recovery and growth in the post-pandemic era.

1. Longitudinal study - 1970s, 1980s, 1990s
 2. Experimental study - 1990s, 2000s, 2010s, 2020s

1. The first step in the process of identifying a problem is to determine the nature of the problem. This involves gathering information about the problem and its context. The second step is to identify the causes of the problem. This involves analyzing the information gathered in the first step to determine the factors that are contributing to the problem. The third step is to develop a plan of action to address the problem. This involves identifying the steps that need to be taken to solve the problem and assigning responsibility for each step. The fourth step is to implement the plan of action. This involves carrying out the steps that have been identified in the plan. The fifth step is to evaluate the results of the plan. This involves determining whether the problem has been solved and whether the plan has been effective. The sixth step is to make adjustments to the plan if necessary. This involves identifying areas where the plan is not working and making changes to improve it. The seventh step is to monitor the problem over time. This involves keeping track of the problem and its progress to ensure that it remains solved and that the plan continues to be effective. The eighth step is to communicate the results of the process. This involves sharing the information about the problem and the plan with others who may be interested in the problem or who may be able to help with it. The ninth step is to document the process. This involves keeping a record of the steps that were taken and the results that were achieved. The tenth step is to review the process. This involves reflecting on the process and identifying areas for improvement. The eleventh step is to share the results of the process. This involves sharing the information about the problem and the plan with others who may be interested in the problem or who may be able to help with it. The twelfth step is to conclude the process. This involves ending the process and moving on to other tasks.

[illegible]

1. *Phragmites australis* (Cav.) Trin. ex Steud.

[illegible]

1. *Chrysomelidae* (1000 spp.)

and the fact that the Commission has not yet received any information from the Government of the United Kingdom regarding the results of its investigation into the matter.

1. *Journal of the American Medical Association*, 1997; 277: 1039-1043.

6. The following are the names of the persons who have been appointed to the various committees of the Board of Directors:

1. The first of these is the fact that the Commission has not yet received any information from the Government of the United States regarding the results of its investigation into the activities of the American Friends Service Committee in the Philippines.

1990

...and the

...and the other is the fact that the system is not yet fully operational.

the 1990s, the number of people in the world who are illiterate has increased from 1.2 billion to 1.5 billion. The number of illiterate people in the world is expected to reach 1.7 billion by the year 2015. The number of illiterate people in the world is expected to reach 1.7 billion by the year 2015. The number of illiterate people in the world is expected to reach 1.7 billion by the year 2015.

[illegible]

the 1990s, the number of people in the world who are illiterate has increased from 400 million to 600 million. The number of illiterate people in the world is expected to increase to 700 million by the year 2015. The number of illiterate people in the world is expected to increase to 800 million by the year 2020. The number of illiterate people in the world is expected to increase to 900 million by the year 2025. The number of illiterate people in the world is expected to increase to 1 billion by the year 2030. The number of illiterate people in the world is expected to increase to 1.1 billion by the year 2035. The number of illiterate people in the world is expected to increase to 1.2 billion by the year 2040. The number of illiterate people in the world is expected to increase to 1.3 billion by the year 2045. The number of illiterate people in the world is expected to increase to 1.4 billion by the year 2050. The number of illiterate people in the world is expected to increase to 1.5 billion by the year 2055. The number of illiterate people in the world is expected to increase to 1.6 billion by the year 2060. The number of illiterate people in the world is expected to increase to 1.7 billion by the year 2065. The number of illiterate people in the world is expected to increase to 1.8 billion by the year 2070. The number of illiterate people in the world is expected to increase to 1.9 billion by the year 2075. The number of illiterate people in the world is expected to increase to 2 billion by the year 2080. The number of illiterate people in the world is expected to increase to 2.1 billion by the year 2085. The number of illiterate people in the world is expected to increase to 2.2 billion by the year 2090. The number of illiterate people in the world is expected to increase to 2.3 billion by the year 2095. The number of illiterate people in the world is expected to increase to 2.4 billion by the year 2100.

the 1990s, the number of people in the world who are illiterate has increased from 400 million to 500 million. The number of illiterate people in the world is expected to increase to 600 million by the year 2015. The number of illiterate people in the world is expected to increase to 700 million by the year 2020. The number of illiterate people in the world is expected to increase to 800 million by the year 2025. The number of illiterate people in the world is expected to increase to 900 million by the year 2030. The number of illiterate people in the world is expected to increase to 1 billion by the year 2035. The number of illiterate people in the world is expected to increase to 1.1 billion by the year 2040. The number of illiterate people in the world is expected to increase to 1.2 billion by the year 2045. The number of illiterate people in the world is expected to increase to 1.3 billion by the year 2050. The number of illiterate people in the world is expected to increase to 1.4 billion by the year 2055. The number of illiterate people in the world is expected to increase to 1.5 billion by the year 2060. The number of illiterate people in the world is expected to increase to 1.6 billion by the year 2065. The number of illiterate people in the world is expected to increase to 1.7 billion by the year 2070. The number of illiterate people in the world is expected to increase to 1.8 billion by the year 2075. The number of illiterate people in the world is expected to increase to 1.9 billion by the year 2080. The number of illiterate people in the world is expected to increase to 2 billion by the year 2085. The number of illiterate people in the world is expected to increase to 2.1 billion by the year 2090. The number of illiterate people in the world is expected to increase to 2.2 billion by the year 2095. The number of illiterate people in the world is expected to increase to 2.3 billion by the year 2100.

the 1990s, the number of people in the world who are illiterate has increased from 400 million to 600 million. The number of illiterate people in the world is expected to reach 700 million by the year 2015. The number of illiterate people in the world is expected to reach 800 million by the year 2020. The number of illiterate people in the world is expected to reach 900 million by the year 2025. The number of illiterate people in the world is expected to reach 1 billion by the year 2030. The number of illiterate people in the world is expected to reach 1.1 billion by the year 2035. The number of illiterate people in the world is expected to reach 1.2 billion by the year 2040. The number of illiterate people in the world is expected to reach 1.3 billion by the year 2045. The number of illiterate people in the world is expected to reach 1.4 billion by the year 2050. The number of illiterate people in the world is expected to reach 1.5 billion by the year 2055. The number of illiterate people in the world is expected to reach 1.6 billion by the year 2060. The number of illiterate people in the world is expected to reach 1.7 billion by the year 2065. The number of illiterate people in the world is expected to reach 1.8 billion by the year 2070. The number of illiterate people in the world is expected to reach 1.9 billion by the year 2075. The number of illiterate people in the world is expected to reach 2 billion by the year 2080. The number of illiterate people in the world is expected to reach 2.1 billion by the year 2085. The number of illiterate people in the world is expected to reach 2.2 billion by the year 2090. The number of illiterate people in the world is expected to reach 2.3 billion by the year 2095. The number of illiterate people in the world is expected to reach 2.4 billion by the year 2100.

Abstract

1. *Pharmaceutical industry*—United States—History.
 2. *Pharmaceutical industry*—United States—Economic aspects.
 3. *Pharmaceutical industry*—United States—Social aspects.
 4. *Pharmaceutical industry*—United States—Government relations.
 5. *Pharmaceutical industry*—United States—Regulation.
 6. *Pharmaceutical industry*—United States—Marketing.
 7. *Pharmaceutical industry*—United States—Research and development.
 8. *Pharmaceutical industry*—United States—Labor relations.
 9. *Pharmaceutical industry*—United States—Ethics.
 10. *Pharmaceutical industry*—United States—Public health.
 11. *Pharmaceutical industry*—United States—Innovation.
 12. *Pharmaceutical industry*—United States—Globalization.
 13. *Pharmaceutical industry*—United States—Patents.
 14. *Pharmaceutical industry*—United States—Competition.
 15. *Pharmaceutical industry*—United States—Consumer protection.
 16. *Pharmaceutical industry*—United States—Quality control.
 17. *Pharmaceutical industry*—United States—Safety.
 18. *Pharmaceutical industry*—United States—Accessibility.
 19. *Pharmaceutical industry*—United States—Sustainability.
 20. *Pharmaceutical industry*—United States—Future trends.
 21. *Pharmaceutical industry*—United States—Policy.
 22. *Pharmaceutical industry*—United States—Legislation.
 23. *Pharmaceutical industry*—United States—Case studies.
 24. *Pharmaceutical industry*—United States—Interviews.
 25. *Pharmaceutical industry*—United States—Surveys.
 26. *Pharmaceutical industry*—United States—Data analysis.
 27. *Pharmaceutical industry*—United States—Comparative studies.
 28. *Pharmaceutical industry*—United States—Historical perspectives.
 29. *Pharmaceutical industry*—United States—Current issues.
 30. *Pharmaceutical industry*—United States—Outlook.
 31. *Pharmaceutical industry*—United States—Challenges.
 32. *Pharmaceutical industry*—United States—Opportunities.
 33. *Pharmaceutical industry*—United States—Stakeholders.
 34. *Pharmaceutical industry*—United States—Partnerships.
 35. *Pharmaceutical industry*—United States—Collaboration.
 36. *Pharmaceutical industry*—United States—Innovation ecosystem.
 37. *Pharmaceutical industry*—United States—Regulatory landscape.
 38. *Pharmaceutical industry*—United States—Market dynamics.
 39. *Pharmaceutical industry*—United States—Consumer behavior.
 40. *Pharmaceutical industry*—United States—Healthcare system.
 41. *Pharmaceutical industry*—United States—Medical professionals.
 42. *Pharmaceutical industry*—United States—Patients.
 43. *Pharmaceutical industry*—United States—Payers.
 44. *Pharmaceutical industry*—United States—Providers.
 45. *Pharmaceutical industry*—United States—Policymakers.
 46. *Pharmaceutical industry*—United States—Academics.
 47. *Pharmaceutical industry*—United States—Journalists.
 48. *Pharmaceutical industry*—United States—Public.
 49. *Pharmaceutical industry*—United States—Media.
 50. *Pharmaceutical industry*—United States—Social media.
 51. *Pharmaceutical industry*—United States—Digital health.
 52. *Pharmaceutical industry*—United States—Telemedicine.
 53. *Pharmaceutical industry*—United States—Artificial intelligence.
 54. *Pharmaceutical industry*—United States—Big data.
 55. *Pharmaceutical industry*—United States—Cloud computing.
 56. *Pharmaceutical industry*—United States—Blockchain.
 57. *Pharmaceutical industry*—United States—Internet of things.
 58. *Pharmaceutical industry*—United States—Wearable devices.
 59. *Pharmaceutical industry*—United States—Mobile health.
 60. *Pharmaceutical industry*—United States—Health informatics.
 61. *Pharmaceutical industry*—United States—Medical devices.
 62. *Pharmaceutical industry*—United States—Biotechnology.
 63. *Pharmaceutical industry*—United States—Nanotechnology.
 64. *Pharmaceutical industry*—United States—Genomics.
 65. *Pharmaceutical industry*—United States—Proteomics.
 66. *Pharmaceutical industry*—United States—Metabolomics.
 67. *Pharmaceutical industry*—United States—Microbiomics.
 68. *Pharmaceutical industry*—United States—Immunomics.
 69. *Pharmaceutical industry*—United States—Neuroscience.
 70. *Pharmaceutical industry*—United States—Oncology.
 71. *Pharmaceutical industry*—United States—Cardiology.
 72. *Pharmaceutical industry*—United States—Endocrinology.
 73. *Pharmaceutical industry*—United States—Immunology.
 74. *Pharmaceutical industry*—United States—Pediatrics.
 75. *Pharmaceutical industry*—United States—Geriatrics.
 76. *Pharmaceutical industry*—United States—Mental health.
 77. *Pharmaceutical industry*—United States—Substance use.
 78. *Pharmaceutical industry*—United States—Addiction.
 79. *Pharmaceutical industry*—United States—Pain management.
 80. *Pharmaceutical industry*—United States—Antibiotics.
 81. *Pharmaceutical industry*—United States—Antivirals.
 82. *Pharmaceutical industry*—United States—Anticancer drugs.
 83. *Pharmaceutical industry*—United States—Immunosuppressants.
 84. *Pharmaceutical industry*—United States—Hormones.
 85. *Pharmaceutical industry*—United States—Vitamins.
 86. *Pharmaceutical industry*—United States—Minerals.
 87. *Pharmaceutical industry*—United States—Herbal products.
 88. *Pharmaceutical industry*—United States—Complementary and alternative medicine.
 89. *Pharmaceutical industry*—United States—Integrative medicine.
 90. *Pharmaceutical industry*—United States—Personalized medicine.
 91. *Pharmaceutical industry*—United States—Precision medicine.
 92. *Pharmaceutical industry*—United States—Regenerative medicine.
 93. *Pharmaceutical industry*—United States—Stem cell therapy.
 94. *Pharmaceutical industry*—United States—Gene therapy.
 95. *Pharmaceutical industry*—United States—Cell therapy.
 96. *Pharmaceutical industry*—United States—Tissue engineering.
 97. *Pharmaceutical industry*—United States—Bioprinting.
 98. *Pharmaceutical industry*—United States—3D printing.
 99. *Pharmaceutical industry*—United States—Nanomedicine.
 100. *Pharmaceutical industry*—United States—Future of medicine.
 101. *Pharmaceutical industry*—United States—Healthcare innovation.
 102. *Pharmaceutical industry*—United States—Medical research.
 103. *Pharmaceutical industry*—United States—Clinical trials.
 104. *Pharmaceutical industry*—United States—Drug development.
 105. *Pharmaceutical industry*—United States—Pharmaceutical innovation.
 106. *Pharmaceutical industry*—United States—Pharmaceutical industry trends.
 107. *Pharmaceutical industry*—United States—Pharmaceutical industry news.
 108. *Pharmaceutical industry*—United States—Pharmaceutical industry analysis.
 109. *Pharmaceutical industry*—United States—Pharmaceutical industry report.
 110. *Pharmaceutical industry*—United States—Pharmaceutical industry overview.
 111. *Pharmaceutical industry*—United States—Pharmaceutical industry landscape.
 112. *Pharmaceutical industry*—United States—Pharmaceutical industry environment.
 113. *Pharmaceutical industry*—United States—Pharmaceutical industry ecosystem.
 114. *Pharmaceutical industry*—United States—Pharmaceutical industry stakeholders.
 115. *Pharmaceutical industry*—United States—Pharmaceutical industry players.
 116. *Pharmaceutical industry*—United States—Pharmaceutical industry companies.
 117. *Pharmaceutical industry*—United States—Pharmaceutical industry organizations.
 118. *Pharmaceutical industry*—United States—Pharmaceutical industry associations.
 119. *Pharmaceutical industry*—United States—Pharmaceutical industry groups.
 120. *Pharmaceutical industry*—United States—Pharmaceutical industry networks.
 121. *Pharmaceutical industry*—United States—Pharmaceutical industry alliances.
 122. *Pharmaceutical industry*—United States—Pharmaceutical industry partnerships.
 123. *Pharmaceutical industry*—United States—Pharmaceutical industry collaborations.
 124. *Pharmaceutical industry*—United States—Pharmaceutical industry joint ventures.
 125. *Pharmaceutical industry*—United States—Pharmaceutical industry mergers and acquisitions.
 126. *Pharmaceutical industry*—United States—Pharmaceutical industry consolidation.
 127. *Pharmaceutical industry*—United States—Pharmaceutical industry restructuring.
 128. *Pharmaceutical industry*—United States—Pharmaceutical industry divestitures.
 129. *Pharmaceutical industry*—United States—Pharmaceutical industry spin-offs.
 130. *Pharmaceutical industry*—United States—Pharmaceutical industry IPOs.
 131. *Pharmaceutical industry*—United States—Pharmaceutical industry public offerings.
 132. *Pharmaceutical industry*—United States—Pharmaceutical industry fundraising.
 133. *Pharmaceutical industry*—United States—Pharmaceutical industry capital markets.
 134. *Pharmaceutical industry*—United States—Pharmaceutical industry investment.
 135. *Pharmaceutical industry*—United States—Pharmaceutical industry venture capital.
 136. *Pharmaceutical industry*—United States—Pharmaceutical industry private equity.
 137. *Pharmaceutical industry*—United States—Pharmaceutical industry hedge funds.
 138. *Pharmaceutical industry*—United States—Pharmaceutical industry sovereign wealth funds.
 139. *Pharmaceutical industry*—United States—Pharmaceutical industry pension funds.
 140. *Pharmaceutical industry*—United States—Pharmaceutical industry endowments.
 141. *Pharmaceutical industry*—United States—Pharmaceutical industry foundations.
 142. *Pharmaceutical industry*—United States—Pharmaceutical industry philanthropy.
 143. *Pharmaceutical industry*—United States—Pharmaceutical industry social responsibility.
 144. *Pharmaceutical industry*—United States—Pharmaceutical industry corporate social responsibility.
 145. *Pharmaceutical industry*—United States—Pharmaceutical industry sustainability.
 146. *Pharmaceutical industry*—United States—Pharmaceutical industry environmental, social, and governance (ESG).
 147. *Pharmaceutical industry*—United States—Pharmaceutical industry diversity and inclusion.
 148. *Pharmaceutical industry*—United States—Pharmaceutical industry employee relations.
 149. *Pharmaceutical industry*—United States—Pharmaceutical industry labor unions.
 150. *Pharmaceutical industry*—United States—Pharmaceutical industry human resources.
 151. *Pharmaceutical industry*—United States—Pharmaceutical industry talent management.
 152. *Pharmaceutical industry*—United States—Pharmaceutical industry recruitment.
 153. *Pharmaceutical industry*—United States—Ph

the 1990s, the number of people in the world who are illiterate has increased from 1.2 billion to 1.5 billion. The number of illiterate people in the world is expected to increase to 1.8 billion by the year 2015. The number of illiterate people in the world is expected to increase to 2.1 billion by the year 2020. The number of illiterate people in the world is expected to increase to 2.4 billion by the year 2025. The number of illiterate people in the world is expected to increase to 2.7 billion by the year 2030. The number of illiterate people in the world is expected to increase to 3.0 billion by the year 2035. The number of illiterate people in the world is expected to increase to 3.3 billion by the year 2040. The number of illiterate people in the world is expected to increase to 3.6 billion by the year 2045. The number of illiterate people in the world is expected to increase to 3.9 billion by the year 2050. The number of illiterate people in the world is expected to increase to 4.2 billion by the year 2055. The number of illiterate people in the world is expected to increase to 4.5 billion by the year 2060. The number of illiterate people in the world is expected to increase to 4.8 billion by the year 2065. The number of illiterate people in the world is expected to increase to 5.1 billion by the year 2070. The number of illiterate people in the world is expected to increase to 5.4 billion by the year 2075. The number of illiterate people in the world is expected to increase to 5.7 billion by the year 2080. The number of illiterate people in the world is expected to increase to 6.0 billion by the year 2085. The number of illiterate people in the world is expected to increase to 6.3 billion by the year 2090. The number of illiterate people in the world is expected to increase to 6.6 billion by the year 2095. The number of illiterate people in the world is expected to increase to 6.9 billion by the year 2100.

[illegible]

1. *Journal of the American Medical Association*, 1997; 277: 1039-1043.

the 1990s, the number of people in the world who are illiterate has increased from 1.2 billion to 1.5 billion. The number of illiterate people in the world is projected to reach 1.7 billion by the year 2015. The number of illiterate people in the world is projected to reach 1.7 billion by the year 2015.

made in the ordinary course of business, a gift received from a relative, a breakfast, luncheon, dinner or other refreshments consisting of food or beverage for immediate consumption, or the occasional provision of transportation within the State of Nebraska.

Relative - means any person related to another by blood or marriage to the third degree of consanguinity, including a foster parent, foster child, step-parent, stepchild, and adopted children and their adoptive parents.

Income - means any money or anything of value received, or to be received as a claim on future services, whether in the form of a fee, salary, expense, allowance, forbearance, forgiveness, interest, dividend, royalty, rent, capital gain, or any other form of recompense then constituting income under the Internal Revenue Code. You need not report a distribution of principal or the income of an irrevocable trust of a member of your immediate family.

Person - means a business, individual, proprietorship, firm, partnership, limited liability company, joint venture, syndicate, business trust, labor organization, company, corporation, association, committee, or any other organization or group of persons acting jointly.

Statutory Definitions: Sections 49-1407, 49-1408, 49-1417, 49-1423, 49-1425, 49-1426, 49-1438, 49-1497, Revised Nebraska Statutes.

Statutory Authority: Sections 49-1493 to 49-1497, Revised Nebraska Statutes.